39824-26-5
39824-26-5 結(jié)構(gòu)式
基本信息
6-氯-(2,3-0-異亞丙基)嘌呤核苷
6-氯-(2,3-O-異亞丙基)嘌呤核苷
6-氯嘌呤-9-(2,3-異丙基亞基-B-D-呋喃核糖苷)
6-CHLORO-9-BETA-D-(2,3-ISOPROPYLIDENE)RIBOFURANOSYLPURINE
6-CHLOROPURINE-9-(2,3-ISOPROPYLIDENE-B-D-RIBOFURANOSIDE)
6-CHLOROPURINE-9-(2,3-ISOPROPYLIDENE-BETA-D-RIBOFURANOSIDE)
6-Chloropurine-9-(2,3-isopropylidene)-b-d-ribfuraniside
6-CHLORO-9-[2,3-O-(ISOPROPYLIDENE)-β-D-RIBOFURONOSYL]-9H-PURINE
6-Chloro-9-b-D-(2,3-isopropylidene)ribofuranosylpurine
6-CHLORO-9-[2.3-0-(ISOPROPYLIDENE)-BETA-D-RIBOFURONOSYL]-9H-PURINE
6-Chloro-9-[2,3-o-(Isopropylid
6-Chloro-9-(2',3'-O-isopropylidene-b-D-ribofuranosyl)purine
6-chloro-9-[230-(isopropylidene)--D-ribofuronosyl]-9H-purine
6-CHLORO-9-[2,3-O-(ISOPROPYLIDENE)-SS-D-RIBOFURONOSYL]-9H-PURINE
6-CHLORO-9-[2'',3''-0-(ISOPROPYLIDENE)-SS-D-RIBOFURONOSYL]-9H-PURINE
6-Chloro-9--D-(2,3-isopropylidene)ribofuranosylpurine
6-Chloropurine-9-(2,3-isopropylidene--D-ribofuranoside)
物理化學(xué)性質(zhì)
制備方法
2004-06-0
67-64-1
39824-26-5
以(3R,4S,5R)-2-(6-氯-9H-嘌呤-9-基)-5-(羥甲基)四氫呋喃-3,4-二醇和丙酮為原料，合成(((3aR,4R,6R,6aR)-6-(6-氯-9H-嘌呤-9-基)-2,2-二甲基四氫呋喃并[3,4-d][1,3]二氧雜環(huán)戊烯-4-基)甲醇的一般步驟如下：向(3R,4S,5R)-2-(6-氯-9H-嘌呤-9-基)-5-(羥甲基)四氫呋喃-3,4-二醇（3.0g，10.5mmol）的無水丙酮（300mL）攪拌懸浮液中加入甲苯磺酸一水合物（19.8g，104mmol）。15分鐘后，固體完全溶解。反應(yīng)2小時后，將反應(yīng)液緩慢倒入攪拌的0.5N NaHCO3水溶液（300mL）中。真空除去丙酮后，用二氯甲烷（DCM，100mL×5）萃取混合物。合并有機層，依次用水（100mL）和鹽水（100mL）洗滌，經(jīng)無水Na2SO4干燥，過濾并濃縮，得到目標產(chǎn)物（3.0g，產(chǎn)率87%，純度>96%）為蒼白色固體。產(chǎn)物經(jīng)1H NMR（500MHz，CD3OD）和LCMS（m/z：327.1 [M+1]+）表征。
參考文獻：
[1] Nucleosides and Nucleotides, 1996, vol. 15, # 1-3, p. 619 - 629
[2] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 7, p. 3848 - 3865
[3] ACS Medicinal Chemistry Letters, 2011, vol. 2, # 8, p. 577 - 582
[4] Patent: WO2012/82436, 2012, A2. Location in patent: Page/Page column 192-193
[5] Patent: WO2012/82436, 2012, A2. Location in patent: Page/Page column 256-257